{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:07:31Z","timestamp":1789142851374,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS131663"],"award-info":[{"award-number":["R01 NS131663"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.mcn.2026.104111","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:19:56Z","timestamp":1783628396000},"page":"104111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Phenotypic screening for small molecules that lower PrP in cultured cells"],"prefix":"10.1016","volume":"138","author":[{"given":"Jeannine A.","family":"Frei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Reidenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo M.H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Mohan","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Casalana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-Anthony","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Laversenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mckenzie","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Auld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Vallabh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mcn.2026.104111_bb0005","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1084\/jem.20172045","article-title":"A role for astroglia in prion diseases","volume":"214","author":"Aguzzi","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mcn.2026.104111_bb0010","author":"AID 743200"},{"key":"10.1016\/j.mcn.2026.104111_bb0015","article-title":"In vivo base editing extends lifespan of a humanized mouse model of prion disease","author":"An","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.mcn.2026.104111_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acs.jnatprod.5b00947","article-title":"Feeling nature\u2019s PAINS: natural products, natural product drugs, and Pan Assay Interference Compounds (PAINS)","volume":"79","author":"Baell","year":"2016","journal-title":"J. Nat. Prod."},{"issue":"20","key":"10.1016\/j.mcn.2026.104111_bb0025","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1074\/jbc.M116.773283","article-title":"Modifiers of prion protein biogenesis and recycling identified by a highly parallel endocytosis kinetics assay","volume":"292","author":"Ballmer","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.mcn.2026.104111_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1083\/jcb.110.3.743","article-title":"Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells","volume":"110","author":"Borchelt","year":"1990","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.mcn.2026.104111_bb0035","first-page":"1","article-title":"High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene","volume":"1","author":"B\u00fceler","year":"1994","journal-title":"Mol. Med. Camb. Mass."},{"issue":"9","key":"10.1016\/j.mcn.2026.104111_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chembiol.2020.07.004","article-title":"Systematic chemogenetic library assembly","volume":"27","author":"Canham","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"10","key":"10.1016\/j.mcn.2026.104111_bb0045","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.mcn.2026.104111_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jvi.63.1.175-181.1989","article-title":"Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells","volume":"63","author":"Caughey","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.mcn.2026.104111_bb0055","article-title":"Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice [Internet]","author":"Chou","year":"2025","journal-title":"bioRxiv"},{"issue":"S6","key":"10.1016\/j.mcn.2026.104111_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/alz.084521","article-title":"Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer\u2019s disease","volume":"20","author":"Cohen","year":"2024","journal-title":"Alzheimers Dement."},{"issue":"5","key":"10.1016\/j.mcn.2026.104111_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1014263","article-title":"PrP turnover in vivo and the time to effect of prion disease therapeutics","volume":"22","author":"Corridon","year":"2026","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.mcn.2026.104111_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent siRNA for prion disease","volume":"54","author":"Gentile","year":"2026","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.mcn.2026.104111_bb0075","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.stemcr.2024.08.010","article-title":"Abnormal synaptic architecture in iPSC-derived neurons from a multi-generational family with genetic Creutzfeldt-Jakob disease","volume":"19","author":"Gojanovich","year":"2024","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.mcn.2026.104111_bb0080","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-021-84689-6","article-title":"Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease","volume":"11","author":"Groveman","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.mcn.2026.104111_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010013","article-title":"Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference","volume":"17","author":"Heinzer","year":"2021","journal-title":"PLoS Pathog."},{"issue":"6701","key":"10.1016\/j.mcn.2026.104111_bb0090","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.mcn.2026.104111_bb0095","author":"Information NC for B"},{"key":"10.1016\/j.mcn.2026.104111_bb0100","author":"Ionis Pharmaceuticals, Inc."},{"issue":"5","key":"10.1016\/j.mcn.2026.104111_bb0105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2006.10.032","article-title":"Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway","volume":"127","author":"Kang","year":"2006","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.mcn.2026.104111_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1073\/pnas.1303510110","article-title":"Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents","volume":"110","author":"Karapetyan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2026.104111_bb0115","article-title":"Fast gene set enrichment analysis [Internet]","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"issue":"1\u20133","key":"10.1016\/j.mcn.2026.104111_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2013.06.014","article-title":"Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960","volume":"715","author":"Laurent","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.mcn.2026.104111_bb0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/1087057110370895","article-title":"Screening cellular feature measurements for image-based assay development","volume":"15","author":"Logan","year":"2010","journal-title":"J. Biomol. Screen."},{"issue":"11","key":"10.1016\/j.mcn.2026.104111_bb0130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3390\/biom11111695","article-title":"p53-Mediated radiosensitization of 177Lu-DOTATATE in neuroblastoma tumor spheroids","volume":"11","author":"Lundsten","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.mcn.2026.104111_bb0135","article-title":"A look at PrP knockdown screen data","author":"Minikel","year":"2015","journal-title":"CureFFI.org [Internet]"},{"key":"10.1016\/j.mcn.2026.104111_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.mcn.2026.104111_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156532","article-title":"Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS","volume":"7","author":"Mortberg","year":"2022","journal-title":"JCI Insight"},{"issue":"6703","key":"10.1016\/j.mcn.2026.104111_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/science.ado7082","article-title":"Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor","volume":"384","author":"Neumann","year":"2024","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.mcn.2026.104111_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1074\/jbc.M111.234393","article-title":"A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets","volume":"286","author":"Poncet-Montange","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.mcn.2026.104111_bb0160","doi-asserted-by":"crossref","first-page":"i430","DOI":"10.1093\/bioinformatics\/btw438","article-title":"Combining dependent P-values with an empirical adaptation of Brown\u2019s method","volume":"32","author":"Poole","year":"2016","journal-title":"Bioinforma. Oxf. Engl."},{"issue":"23","key":"10.1016\/j.mcn.2026.104111_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2026.104111_bb0170","first-page":"5","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"30","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"issue":"39","key":"10.1016\/j.mcn.2026.104111_bb0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1074\/jbc.RA120.014905","article-title":"Multimodal small-molecule screening for human prion protein binders","volume":"295","author":"Reidenbach","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mcn.2026.104111_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.mcn.2026.104111_bb0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From failure to meet the clinical endpoint to U.S. Food and Drug Administration Approval: 15th antisense oligonucleotide therapy approved qalsody (Tofersen) for treatment of SOD1 mutated amyotrophic lateral sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther."},{"issue":"12","key":"10.1016\/j.mcn.2026.104111_bb0190","doi-asserted-by":"crossref","first-page":"7586","DOI":"10.1128\/jvi.69.12.7586-7592.1995","article-title":"Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent","volume":"69","author":"Sakaguchi","year":"1995","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.mcn.2026.104111_bb0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bmc.2014.01.001","article-title":"Novel compounds lowering the cellular isoform of the human prion protein in cultured human cells","volume":"22","author":"Silber","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.mcn.2026.104111_bb0200","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"D1","key":"10.1016\/j.mcn.2026.104111_bb0205","doi-asserted-by":"crossref","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","article-title":"UniProt: the universal protein knowledgebase","volume":"45","author":"The UniProt Consortium","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.mcn.2026.104111_bb0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","article-title":"Towards a treatment for genetic prion disease: trials and biomarkers","volume":"19","author":"Vallabh","year":"2020","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.mcn.2026.104111_bb0215","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1093\/bioinformatics\/bty441","article-title":"ggCyto: next generation open-source visualization software for cytometry","volume":"34","author":"Van","year":"2018","journal-title":"Bioinformatics"},{"issue":"20","key":"10.1016\/j.mcn.2026.104111_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bmcl.2018.08.027","article-title":"In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor","volume":"28","author":"Vaupel","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6689","key":"10.1016\/j.mcn.2026.104111_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.adp3043","article-title":"Foiling deadly prions","volume":"383","author":"Wadman","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mcn.2026.104111_bb0230","first-page":"2","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostat. Oxf. Engl."}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743126000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743126000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:18:11Z","timestamp":1789139891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044743126000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S1044743126000412"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2026.104111","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic screening for small molecules that lower PrP in cultured cells","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcn.2026.104111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104111"}}